| 0.5397 -0.021 (-3.8%) | 04-22 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.74 | 1-year : | 0.85 |
| Resists | First : | 0.64 | Second : | 0.72 |
| Pivot price | 0.58  |
|||
| Supports | First : | 0.5 | Second : | 0.41 |
| MAs | MA(5) : | 0.58 |
MA(20) : | 0.59 |
| MA(100) : | 0.59  |
MA(250) : | 0.77 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 26.2 |
D(3) : | 35.5 |
| RSI | RSI(14): 37.9 |
|||
| 52-week | High : | 1.5 | Low : | 0.36 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ XCUR ] has closed above bottom band by 4.5%. Bollinger Bands are 51.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 19 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.57 - 0.57 | 0.57 - 0.57 |
| Low: | 0.52 - 0.53 | 0.53 - 0.53 |
| Close: | 0.53 - 0.54 | 0.54 - 0.54 |
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Mon, 05 Feb 2024
Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the ... - Business Wire
Mon, 05 Feb 2024
Exicure Inc Announces Licensing Patents for Therapeutic Advancement - TipRanks.com - TipRanks
Fri, 08 Dec 2023
Why Is Exicure (XCUR) Stock Up 57% Today? - InvestorPlace
Tue, 28 Nov 2023
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q - Yahoo Finance
Fri, 14 Jul 2023
Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update - Business Wire
Thu, 04 May 2023
Exicure, Inc. Announces Investment in Korean SNS Platform Cyworld - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 45 (%) |
| Held by Institutions | 9.8 (%) |
| Shares Short | 181 (K) |
| Shares Short P.Month | 201 (K) |
| EPS | 1.76 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.12 |
| Profit Margin | 12.8 % |
| Operating Margin | 13.4 % |
| Return on Assets (ttm) | 7.3 % |
| Return on Equity (ttm) | 56.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 2.75 |
| EBITDA (p.s.) | 0.49 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -22 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | 0.3 |
| PEG Ratio | 0 |
| Price to Book value | 0.48 |
| Price to Sales | 0.19 |
| Price to Cash Flow | -0.22 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|